Login to Your Account

In The Clinic NEWS

Verastem Inc. shares began climbing out of the hole dug Wednesday by Twitter wags who chastised the firm about the deaths in a phase II trial with defactinib of two late-stage lung cancer patients who "were really pretty sick in many different ways" beyond their primary disease, CEO Robert Forrester told BioWorld Today. "We've had a number of patients who have died between screening and first dose, i.e., before they even see the drug. That gives you the context for what we're trying to do here."

LONDON – Tigenix NV is claiming the crown as first to deliver positive phase III data in an allogeneic stem cell therapy, reporting statistically significant results for Cx601 in the treatment of complex perianal fistulas caused by Crohn's disease.
Macrocure Ltd. shares (NASDAQ:MCUR) hit an all-time low on Thursday after a futility analysis of partial data from a pivotal phase III study revealed that the company's sole candidate, the cell therapy Curexcell, is unlikely to meet its primary endpoint of helping heal venous leg ulcers faster than a placebo.
More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: